Increlex (mecasermin [rDNA origin] injection)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) March 2016 ADVERSE REACTIONS Immunogenicity As with all therapeutic proteins, there is potential for immunogenicity. The...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts